These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1119 related items for PubMed ID: 26333104

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
    Brahmi M, Thiesse P, Ranchere D, Mognetti T, Pinson S, Renard C, Decouvelaere AV, Blay JY, Combemale P.
    PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A.
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Derlin T, Tornquist K, Münster S, Apostolova I, Hagel C, Friedrich RE, Wedegärtner U, Mautner VF.
    Clin Nucl Med; 2013 Jan; 38(1):e19-25. PubMed ID: 23242059
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A, Chaudhry M, Blakeley JO, Wahl R.
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
    Reinert CP, Schuhmann MU, Bender B, Gugel I, la Fougère C, Schäfer J, Gatidis S.
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE, Lucas JD, O'Doherty MJ, Hughes RA, Smith MA, Cronin BF, Bingham J.
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Association between benign and malignant peripheral nerve sheath tumors in NF1.
    Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM.
    Neurology; 2005 Jul 26; 65(2):205-11. PubMed ID: 16043787
    [Abstract] [Full Text] [Related]

  • 14. The role of magnetic resonance imaging in the diagnostic evaluation of malignant peripheral nerve sheath tumors.
    Chhabra A, Soldatos T, Durand DJ, Carrino JA, McCarthy EF, Belzberg AJ.
    Indian J Cancer; 2011 Jul 26; 48(3):328-34. PubMed ID: 21921333
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intraosseous malignant peripheral nerve sheath tumor in a patient with neurofibromatosis.
    Terry DG, Sauser DD, Gordon MD.
    Skeletal Radiol; 1998 Jun 26; 27(6):346-9. PubMed ID: 9677654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.